ClinicalTrials.gg
CompletedNCT02795117Updated Nov 2, 2021Results posted

Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea

A Phase 3 interventional study of Ivermectin and Ivermectin (reference) in Rosacea, sponsored by Padagis LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.

Enrollment
6th of 11
486 · median 486
Started
2016
with 1 other
Phase 3
6 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Padagis LLC

Among the 11 studies testing ivermectin in Rosacea, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 6th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ivermectin in Rosacea as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must sign an Institutional Review Board (IRB) approved written for this study.
  2. Must be at least 18 years of age
  3. Must have a definite clinical diagnosis of moderate to severe facial papulopustular rosacea
  4. Subjects must be willing and able to understand and comply with the requirements of the study and apply the medication as instructed.
  5. Subjects must be in general good health and free from any disease, other than rosacea, that might interfere with the study evaluations.
  6. Females of (excluding women who are surgically sterilized (verified tubal ligation or bilateral oophorectomy or hysterectomy) or post- menopausal for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day 1 (Baseline), must be willing to use an acceptable form of during the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation.
  2. Current or past ocular rosacea.
  3. Presence of any other facial skin condition that might interfere with rosacea diagnosis and/or assessment.
  4. History of or allergy to the study medication and/or any ingredient in the study medication.
  5. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit 1/Day 1 (Baseline).
  6. Current use of anticoagulation therapy and use throughout the study.
  7. Use of medicated make-up (including anti-aging make-up) throughout the study
  8. Use during the study of 1) systemic , 2) topical retinoids to the face 3) antibiotics known to impact rosacea 4) agents, or immunomodulators).
  9. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics.
  10. Use of medicated cleansers on the face (throughout the study.
  11. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements
  12. Use of topical astringents or abrasives, medicated topical preparations (prescription and OTC products) within 2 days prior to Visit 1 and throughout the study.
  13. Use of antipruritics (including antihistamines), spa treatments or chlorine exposure (swimming etc.) within 24 hours of all study visits.
  14. Participation in any clinical study involving an product, agent or device that might influence the intended effects or mask the side effects of study medication in the 1 month (30 days) prior Visit 1/Day 1 (Baseline) or throughout the study.
  15. Previous enrollment in this study or current enrollment in this study at another participating site.
  16. Use of tanning booths, sun lamps (excessive UV radiation e.g., phototherapy, daily extended exposure or occupational exposure to the sun), sunbathing or excessive exposure to the sun 1 week prior to baseline and throughout the study.
  17. Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
486 participants (actual)

Study arms

  • Experimental
    Test product

    Drug: Ivermectin

  • Active comparator
    Reference product

    Drug: Ivermectin (reference)

  • Placebo comparator
    Placebo product

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count

    Time frame: Day 1 to Day 84

Secondary outcomes

  1. Subjects With Clinical Success on the Investigator Global Assessment

    Clinical success is defined as a score of clear or almost clear

    Time frame: Day 1 to Day 84

07

Results

Posted Jan 5, 2021

Participant flow

Participant flow — Overall Study
MilestoneTest ProductReference ProductPlacebo
Started193193100
Completed17516688
Not completed182712

Outcome measures

PrimaryMean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count
Time frame:
Day 1 to Day 84
Reported as:
Mean · percentage of lesion reduction
Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count
percentage of lesion reductionTest ProductReference ProductPlacebo
Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count65.47 ± 30.22267.89 ± 30.24455.51 ± 32.660
Statistical analysis
  • Test Product vs Reference Product · ANOVA · Equivalence ratio: 96.4 · 90% CI 91.0 to 105.4
SecondarySubjects With Clinical Success on the Investigator Global Assessment

Clinical success is defined as a score of clear or almost clear

Time frame:
Day 1 to Day 84
Reported as:
Count of participants · Participants
Subjects With Clinical Success on the Investigator Global Assessment
ParticipantsTest ProductReference ProductPlacebo
Subjects With Clinical Success on the Investigator Global Assessment717926
Statistical analysis
  • Test Product vs Reference Product · Wald's method · Equivalence difference: -6.48 · 90% CI -18.31 to 1.85

Adverse events

Collected over Day 1 to day 84. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product0/193 (0%)0/193 (0%)0/193 (0%)
Reference Product0/193 (0%)0/193 (0%)0/193 (0%)
Placebo0/100 (0%)0/100 (0%)0/100 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Test ProductReference ProductPlaceboTotal
Mean51.9 ± 12.6551.3 ± 13.6151.2 ± 14.2551.5 ± 13.35
Sex: Female, Male
Sex: Female, Male(Participants)Test ProductReference ProductPlaceboTotal
Female14114067348
Male525333138
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test ProductReference ProductPlaceboTotal
Hispanic or Latino38371994
Not Hispanic or Latino15515681392
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test ProductReference ProductPlaceboTotal
American Indian or Alaska Native0011
Asian3205
Native Hawaiian or Other Pacific Islander1102
Black or African American0022
White18818997474
More than one race0000
Unknown or Not Reported1102
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Feb 2017, 9 months.

Results were first posted in Jan 2021, 3 years 11 months after primary completion. A results delay was requested in Feb 2018.

Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2016
First posted
Jun 9, 2016
StartActual
May 2016
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Results delay requested
Feb 19, 2018
Results first posted
Jan 5, 2021
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02795117
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Jun 9, 2016
Start date
May 2016
Primary completion
Feb 2017
Completion
Feb 2017
Results posted
Jan 5, 2021
Last update
Nov 2, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion